Ticagrelor: Research, Dosing, and Where to Buy in 2026
A research-first profile for Ticagrelor (taika galore, Brilinta, bralinta), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Ticagrelor is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers for Ticagrelor, each linked to its source.
- Also indexed as taika galore, Brilinta, bralinta.
- 0 aggregated dosing-protocol mentions from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is Ticagrelor?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Ticagrelor Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
No transcript-derived dosing mentions in current source set.
Where to Buy Ticagrelor in 2026
No tracked vendor recommendations for Ticagrelor yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Ticagrelor. Each line links to the original source.
- "Co-primary net clinical benefit outcome consisted of all-cause death, myocardial infarction, stroke, PLATO major and minor bleeding (non-inferiority hypothesis, margin of 2%)." · Gimbel M et al, 2020 PubMed
- "Because 475 (95%) patients received ticagrelor in the ticagrelor or prasugrel group, we will refer to this group as the ticagrelor group." · Gimbel M et al, 2020 PubMed
- "Premature discontinuation of the study drug occurred in 238 (47%) of 502 ticagrelor group patients randomly assigned to ticagrelor, and in 112 (22%) of 500 patients randomly assigned to clopidogrel." · Gimbel M et al, 2020 PubMed
- "Primary bleeding outcome was significantly lower in the clopidogrel group (88 [18%] of 500 patients) than in the ticagrelor group (118 [24%] of 502; hazard ratio 0·71, 95% CI 0·54 to 0·94; p=0·02 for superiority)." · Gimbel M et al, 2020 PubMed
- "Co-primary net clinical benefit outcome was non-inferior for the use of clopidogrel (139 [28%]) versus ticagrelor (161 [32%]; absolute risk difference -4%, 95% CI -10·0 to 1·4; p=0·03 for non-inferiority)." · Gimbel M et al, 2020 PubMed
Research and Studies
8 PubMed-indexed papers reference Ticagrelor. Top 8 shown.
Legal Status
Ticagrelor is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Ticagrelor FDA-approved?
Ticagrelor is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
How much research has been published on Ticagrelor?
8 PubMed-indexed paper(s) reference Ticagrelor in our current research feed. See the Research and Studies section above for citations.